There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Gilead Sciences (GILD – Research Report) and Dexcom (DXCM – Research Report) with bullish sentiments.
Regeneron (REGN)
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Regeneron, with a price target of $1060.00. The company’s shares closed last Thursday at $890.68.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $1042.00, a 14.4% upside from current levels. In a report issued on April 10, Leerink Partners also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Gilead Sciences (GILD)
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences yesterday and set a price target of $80.00. The company’s shares closed last Thursday at $65.27, close to its 52-week low of $65.09.
According to TipRanks.com, Yee is a 1-star analyst with an average return of
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $83.42, implying a 23.6% upside from current levels. In a report issued on April 11, J.P. Morgan also maintained a Buy rating on the stock with a $95.00 price target.
Dexcom (DXCM)
Jefferies analyst Matthew Taylor maintained a Buy rating on Dexcom yesterday and set a price target of $160.00. The company’s shares closed last Thursday at $138.01, close to its 52-week high of $142.00.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $153.73 average price target, representing a 10.7% upside. In a report issued on April 10, UBS also maintained a Buy rating on the stock with a $163.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Regeneron, Mammoth collaborate to purse next-generation gene editing
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
- Regeneron price target raised to $1,030 from $1,020 at TD Cowen
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
- Regeneron price target raised to $720 from $710 at BofA
